tirzepatide shortage news october 2025 September 2, 2025: U.S. compounding restrictions have stemmed a flood of compounded semaglutide and – Partnership for Safe Medicines Mounjaro and Zepbound no longer

The healthcare professionals are licensed in your state

Known by the brand name Mounjaro, this once-weekly injection targets both GLP-1 and GIP hormones, helping regulate appetite and blood sugar levels while supporting sustainable weight loss and a healthier lifestyle

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus under the brand name Mounjaro and for chronic weight management under the brand name Zepbound

If you experience any changes in energy levels or digestion, consult your doctor to adjust your treatment plan accordingly

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease

Total room temperature exposure is approximately 48 to 60 hours